Precision Biosciences has patented a mitochondria-targeting engineered meganuclease (MTEM) that can modify human mitochondrial DNA. This technology allows for precise editing of eukaryotic cells, potentially leading to advancements in genetic modification research. GlobalData’s report on Precision Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Precision Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Precision Biosciences, Gene splicing using nucleases was a key innovation area identified from patents. Precision Biosciences's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Engineered meganucleases for modifying human mitochondrial dna

Source: United States Patent and Trademark Office (USPTO). Credit: Precision Biosciences Inc

A recently granted patent (Publication Number: US11866747B2) discloses a novel mitochondria-targeting engineered meganuclease (MTEM) designed to bind and cleave specific recognition sequences within mitochondrial genomes of eukaryotic cells. The MTEM consists of an engineered meganuclease fused with a mitochondrial transit peptide (MTP), with the engineered meganuclease sequence specified in SEQ ID NO: 9. Additionally, the MTP sequence is detailed in SEQ ID NO: 45 and is attached at the N-terminus of the engineered meganuclease. Furthermore, the MTEM may also be linked to a nuclear export sequence (NES) detailed in SEQ ID NO: 46 at the C-terminus.

Moreover, the patent encompasses the use of polynucleotides encoding the MTEM, with similar structural and functional characteristics as the MTEM described above. These polynucleotides can be incorporated into recombinant adeno-associated viruses (AAVs) for targeted delivery and expression of the MTEM within eukaryotic cells. The AAVs containing the polynucleotide encoding the MTEM are equipped with a promoter, such as the CAG promoter, operably linked to the nucleic acid sequence encoding the MTEM. Additionally, specific AAV capsids, like AAV9, can be utilized for packaging the polynucleotide-containing AAVs, further enhancing their targeted delivery capabilities. The patent outlines various combinations and configurations of the MTEM, MTP, NES, and AAV components, providing a comprehensive framework for utilizing this innovative technology in genetic engineering applications.

To know more about GlobalData’s detailed insights on Precision Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies